Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compass Pathways plc (Nasdaq: CMPS) SEC filings page provides access to the company’s regulatory disclosures as it develops COMP360, an investigational synthetic psilocybin treatment for serious mental health conditions. As a foreign private issuer incorporated in England and Wales and listed on the Nasdaq Global Select Market, Compass reports key information to the U.S. Securities and Exchange Commission through forms such as Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q.
Current reports on Form 8-K for CMPS include items on financial results, clinical milestones, and corporate governance. For example, Compass has filed 8-Ks to furnish press releases announcing financial results for periods ended June 30 and September 30, 2025, and to report board changes such as the appointments of new directors and related compensation arrangements. Other 8-K filings describe clinical developments, including achievement of the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant depression.
Investors can also use this page to track periodic reports (10-K and 10-Q), which contain detailed discussions of Compass Pathways’ business, risk factors, clinical programs for treatment-resistant depression and post-traumatic stress disorder, and financial statements. These documents elaborate on topics such as research and development spending, funding needs, and the risks inherent in clinical development and regulatory review of COMP360.
In addition, this filings page can surface governance and compensation disclosures, including information about director appointments, option grants under the company’s share option and incentive plan, and indemnity arrangements, as reflected in specific 8-K items. Real-time updates from EDGAR combined with AI-powered summaries can help readers quickly understand the key points of lengthy filings, from clinical data descriptions to financial condition discussions, without reading every page of the underlying documents.
Compass Pathways plc (CMPS) filed an 8-K to disclose that its pivotal Phase 3 COMP005 study met its primary endpoint in treatment-resistant depression (TRD). In the randomized, double-blind trial (n = 258 across 32 U.S. sites), a single 25 mg dose of COMP360 psilocybin produced a statistically significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores versus placebo at week 6 (mean difference −3.6 points; 95% CI [−5.7, −1.5]; p < 0.001). Safety, reviewed by the independent DSMB on 19 June 2025, was consistent with prior studies and showed no new or unexpected adverse signals, including suicidality.
COMP005 has three parts, with Parts A (through week 6) now unblinded, Part B blinded to week 26, and Part C open-label through week 52. The parallel COMP006 trial (planned n = 568) compares two fixed dosing regimens and remains blinded. The company expects to release 26-week data for COMP005 after all COMP006 participants complete Part A; 26-week COMP006 data are targeted for H2 2026.
The positive read-out strengthens CMPS’s regulatory pathway, but the FDA has not yet reviewed the data, full safety assessments are pending, and additional capital will likely be required to complete development and pursue commercialization. Forward-looking statements highlight clinical, regulatory, and financing risks.